UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes
Executive Summary
The UK cost-effectiveness watchdog NICE delivered a resounding "no" Feb. 9 to the use on the National Health Service of Bristol-Myers Squibb's Sprycel (dasatinib) and Novartis' Tasigna (nilotinib) in chronic myeloid leukemia patients who are intolerant to Glivec (imatinib, Gleevec in the U.S.)
You may also be interested in...
With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.
NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
A lack of good clinical trial data on the use of Sprycel, high-dose Glivec and Tasigna in imatinib-resistant chronic myeloid leukemia patients leads to rejection by NICE in a draft guidance.
Tasigna Beats Sprycel To First-Line CML Punch
Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib)